Paclitaxel Carboplatin
Found 4 free book(s)
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eupaclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1). Tecentriq, in combination with nab - paclitaxel and carboplatin, is indicated for the first -line treatment of adult patients with metastatic non- squamous NSCLC who do not have EGFR mutant or
NCCN Clinical Practice Guidelines in Oncology NCCN ...
www2.tri-kobe.orgCarboplatin + albumin-bound paclitaxel + atezolizumab as an "other recommended" treatment option as a category 2A. Nivolumab + ipilimumab as an "other recommended" treatment option as a category 2A. NSCL-J 3 of 4 • The following treatment options added for patients with metastatic squamous cell NSCLC, PD-L1 <1%, and PS 0-1.
Extravasation/Infiltration Management Chart
pedsrx.johnshopkins.eduCARBOplatin X € With or without pain Carmustine X € Cool to touch CISplatin* X X € Edema <1" in any direction Cladribine X X € Skin blanched Cyclophosphamide X X € With or without pain Cytarabine X X € Cool to touch Dacarbazine X € Edema 1-6" in any direction Dactinomycin* X € Skin blanched, translucent DAUNorubicin* X X €
POTENTIAL IRRITANT MEDICATIONS
mi-hms.orgPOTENTIAL IRRITANT MEDICATIONS * (Consider administration via central venous catheter – should not administer via Midline) *An irritant is an agent capable of producing discomfort or pain along the internal lumen of the vein (s 105 INS SOP …